Tempest Therapeutics, Inc.
TPST
$6.90
$0.294.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.73% | 16.21% | 19.50% | 9.97% | 3.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.24% | 44.13% | 16.50% | -3.34% | -13.24% |
| Operating Income | -52.24% | -44.13% | -16.50% | 3.34% | 13.24% |
| Income Before Tax | -50.54% | -41.88% | -14.18% | 4.57% | 14.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.54% | -41.88% | -14.18% | 4.57% | 14.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.54% | -41.88% | -14.18% | 4.57% | 14.62% |
| EBIT | -52.24% | -44.13% | -16.50% | 3.34% | 13.24% |
| EBITDA | -52.77% | -44.69% | -17.07% | 2.75% | 12.57% |
| EPS Basic | 19.59% | 22.03% | 29.61% | 31.77% | 34.05% |
| Normalized Basic EPS | 19.59% | 22.03% | 29.61% | 31.77% | 34.05% |
| EPS Diluted | 19.59% | 22.03% | 29.61% | 31.77% | 34.05% |
| Normalized Diluted EPS | 19.59% | 22.03% | 29.61% | 31.77% | 34.05% |
| Average Basic Shares Outstanding | 91.63% | 81.50% | 61.61% | 41.89% | 32.67% |
| Average Diluted Shares Outstanding | 91.63% | 81.50% | 61.61% | 41.89% | 32.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |